Changfu Li
Papers
1
Total Citations
12
H-Index
1
About
Changfu Li is a pioneering urologic surgeon and researcher whose work centers on advancing robotic-assisted surgery, particularly for prostate and kidney cancer treatments. His major contributions lie in the rigorous clinical evaluation of emerging Chinese robotic surgical systems, most notably the KangDuo-SR-2000 and EDGE MP1000, comparing their safety and efficacy directly against the established Da Vinci Xi system. His landmark prospective, non-randomized clinical trial, published in 2025, demonstrated non-inferior outcomes for these domestic platforms in robot-assisted partial nephrectomy and radical prostatectomy, a finding with profound implications for surgical accessibility and cost reduction. With over 12 citations already for this pivotal study, Li’s work is rapidly shaping the global conversation on surgical robotics. Beyond this trial, his research portfolio explores perioperative outcomes and innovative techniques in minimally invasive urology. By validating homegrown technologies, Changfu Li is not only expanding surgical options but also fostering technological sovereignty, making him a key figure in the next generation of robotic surgery.
Research Focus
Key Achievements
Top Papers
- 1